乳酸中介的miRNA调节癌症治疗耐药性
Yiyi Shou1,2, Ruiqi Liu3, Hao Xiong1
1Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
Journal of translational medicine
|August 20, 2025
概括
乳酸是一种乳酸修饰,通过改变新陈代谢,表观遗传学和免疫反应与microRNA相互作用来驱动癌症治疗抵抗. 针对这种交叉通话提供了新的治疗策略和预测耐药性的生物标志物.
科学领域:
- 癌症生物学
- 代谢重编程
- 表观遗传学
- 免疫调节
- 翻译后的修改
- 微RNA网络
背景情况:
- 癌症的治疗耐药性涉及瘤代谢,表观遗传学和免疫调节的复杂相互作用.
- 乳酸化是一种乳酸衍生后翻译性修饰,将代谢变化与基因表达联系起来.
- 微RNAs (miRNAs) 调节代谢适应性和表观遗传可塑性,但它们与乳酸酶的相互作用尚未得到充分研究.
研究的目的:
- 综合评估乳化-miRNA交叉对抗癌症治疗的新兴领域.
- 阐明乳化和miRNAs相互作用以影响瘤生物学和治疗结果的机制.
- 根据这种交叉语音识别潜在的治疗策略和生物标志物.
主要方法:
- 对乳化,miRNA和癌症耐药性的现有文献进行审查和结构化评估.
- 涉及基因子/蛋白质和miRNA网络的调控框架的分析.
- 通过细胞外囊泡检查依赖乳酸的miRNA信号及其对瘤微环境的影响.
主要成果:
- 乳化激活致癌的miRNAs,这反过来又加强了糖溶性流和乳化酶的活性,从而产生了反循环.
- 乳酸积累在压力下抑制特定的miRNA,稳定DNA修复和支持生存的途径.
- 乳化介导的miRNA信号有助于T细胞耗尽和M2巨细胞分化,促进免疫抑制.
结论:
- 乳化-miRNA交叉对抗是癌症治疗中一个主要的调节轴.
- 联合向策略 (例如LDHA和致癌性miRNA) 和液体活检 (H3K18la,miRNA标记) 显示出治疗潜力.
- 整合代谢,表观遗传和免疫学的观点对于开发新的机理驱动的癌症干预措施至关重要.
相关概念视频
01:22MicroRNAs
3.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:39lncRNA - Long Non-coding RNAs
8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
01:46Epigenetic Regulation
31.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.4K